Cost-Effectiveness Opinions by French National Health Authority Improved Pricing Decisions

Published Feb 18, 2019

Lessons from the Recent Uptake of Health Economic Evaluation of Innovative Drugs in the French Regulatory Framework

Lawrenceville, NJ, USA—February 18, 2019—Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced today the publication of new research showing that the use of cost-effectiveness opinions issued by the French National Health Authority improved the information available to support the pricing decisions for new hepatitis C drugs. The report, “Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs,” was published in the February 2019 issue of Value in Health. Taking the example of new direct-acting antivirals—sofosbuvir (Sovaldi®), simeprevir (Olysio®), daclatasvir (Daklinza®), ledipasvir-sofosbuvir (Harvoni®), ombitasvir-combo (Viekirax®), and dasabuvir (Exviera®)—against hepatitis C virus, the authors assessed whether and how the cost-effectiveness opinions issued by the French National Health Authority improved the information available to support pricing decisions. More precisely, the analysis examined what specific information—if any—was provided on the drugs’ value. The research results show that the cost-effectiveness opinions did in fact bring to the fore 3 issues prone to impact the incremental cost utility ratio but were not available to decision makers through clinical opinions or published cost-utility analysis: 1) the stage of treatment initiation, 2) the modeling of the disease progression, and 3) the uncertainty around the efficacy rates. Therefore, the analysis shows that, in the case of the direct-acting antivirals, the use of cost-effectiveness opinions has enhanced the information available to the decision makers on the value of the treatments. “Since 2013, pharmaceutical manufacturers have been required to submit an economic dossier to the French Health Authority for market access,” said author Valerie Clement, MRE, Faculte d’Economie, Universite de Montpellier, Montpellier, France. “The Commission d’Evaluation Economique et de Sante Publique is in charge of the review and issues a cost-effectiveness opinion. These opinions assess the reliability and the methodological consistency of the dossier and provide comments that highlight the salient features of the drugs’ value for money (essentially, adding health economic evaluation to the clinical evaluation of the drugs). Among the very first drugs subject to this new regulatory framework were the newest direct-acting antivirals for hepatitis C virus. This paper constitutes the first attempt to draw lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework.”

###

ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: www.linkedin.com/company/ispororg | Twitter: www.twitter.com/ispororg (@ISPORorg) | YouTube: www.youtube.com/ispororg | Facebook: www.facebook.com/ispororg | Instagram: www.instagram.com/ispororg   ABOUT VALUE IN HEALTH Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2017 impact factor score is 5.494. Value in Health is ranked 3rd among 94 journals in healthcare sciences and services, 3rd among 79 journals in health policy and services, and 6th among 353 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world. Web: www.ispor.org/valueinhealth | Twitter: www.twitter.com/isporjournals (@ISPORjournals)

Related Stories

Health Technology Assessment Around the World: Broadening the Understanding of Cross-Country Differences

Jan 22, 2020

Value in Health announced today the publication of a series of articles investigating the use of health technology assessment (HTA) in healthcare decision making across the globe. The series, “HTA Around the World—Influences of Culture, Values, and Institutions,” appears in the January 2020 issue of Value in Health.

Introducing “Health Years in Total:” A Novel Framework for Valuing Health Outcomes in Cost-Effectiveness Analyses

Jan 21, 2020

Value in Health announced today the publication of an article introducing a new framework for valuing health outcomes in cost-effectiveness analyses. This new metric, “health years in total,” is a robust approach that overcomes specific limitations of quality-adjusted life-year and equal value of life measures.

ISPOR Recognized by MarCom Awards for Its Annual Report and Rebranding of Value in Health

Dec 3, 2019

ISPOR announced that it has won a number of MarCom Awards recognizing the rebranding of its high-impact journal Value in Health and for its 2018 Annual Report.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×